TERNS PHARMACEUTICALS INC (TERN)

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 46 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity. Its product pipeline includes TERN-701, TERN-501, TERN-601 and TERN-101. ItsTERN-701 is an oral, potent, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) specifically targeting the ABL myristoyl pocket for chronic myeloid leukemia. The TERN-501 is its highly selective thyroid hormone receptor beta (THR-b) agonist for non-alcoholic steatohepatitis (NASH) in Phase IIa clinical development. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist for metabolic diseases such as obesity. TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver.

Company Info

TERNS PHARMACEUTICALS INC

1065 East Hillsdale Blvd., Suite 100, Suite 100

Foster City CALIFORNIA 94404

P: 16505255535

CEO: Senthil Sundaram

Employees: 46

Website: https://ternspharma.com/